PTH treatment (3 times a day) increases LT- and ST-HSCs both phenotypically and functionally. (A) Frequency of MPP/ST-HSCs from VEH- or PTH-treated mice based on cell surface expression of CD150 and CD48, as shown in Figure 2. (B) Phenotypic quantification of LT-HSCs based on surface expression of CD150 and CD48, as shown in Figure 2. (C-E) Representative flow cytometry plots depicting the isolation of MPP, ST-HSCs, and LT-HSCs. (F) Frequency of the MPP population of cells as defined by panel E. (G) Frequency of the ST-HSC population of cells as defined by panel E. (H) Analysis of the peripheral blood after primary competitive transplantation shows the percentage of donor cells determined by cell surface expression of CD45.1 in the CD11b⁺, B220⁺, and CD3e⁺ population of cells. Recipient mice were analyzed at 3 weeks (top panel), 6 weeks (middle panel), and 12 weeks (bottom panel) after transplantation of donor and competitor cells. (I) Analysis of the peripheral blood from secondary transplantation recipient mice was performed at 6 weeks (top panel), 12 weeks (middle panel), and 16 weeks (bottom panel) after transplantation. *P < .05. **P < .01. ***P < .001. n = 6 per treatment group, 3 donors per treatment group, 10 to 20 recipients per treatment group.